Skip to content

Research at St Andrews

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects.
Methods: FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762.
Findings: Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839-1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26-6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38-2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months.
Interpretation: Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function.
Close

Details

Original languageEnglish
Pages (from-to)265-274
Number of pages10
JournalLancet
Volume393
Issue number10168
Early online date5 Dec 2018
DOIs
Publication statusPublished - 19 Jan 2019

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Over-use of thyroid testing in Canadian and UK primary care in frequent attenders: a cross-sectional study

    Crampton, N., Kalia, S., Del Giudice, M. E., Wintemute, K., Sullivan, F., Aliarzadeh, B., Meaney, C., Moineddin, R., Singer, A., Hinton, W., Sherlock, J., Williams, J., de Lusignan, S. & Greiver, M., 28 Mar 2021, In: International Journal of Clinical Practice. Early Vew, e14144.

    Research output: Contribution to journalArticlepeer-review

  2. Trends in diabetes medication use in Australia, Canada, England, and Scotland: A repeated cross-sectional analysis in primary care

    Greiver, M., Havard, A., Bowles, J. K. F., Kalia, S., Chen, T., Aliarzadeh, B., Moineddin, R., Sherlock, J., Hinton, W., Sullivan, F., O'Neill, B., Pow, C., Bhatt, A., Rahman, F., Meza-Torres, B., Litchfield, M. & de Lusignan, S., Mar 2021, In: British Journal of General Practice. 71, 704, p. E209-E218

    Research output: Contribution to journalArticlepeer-review

  3. Trends in diabetes medication use in Canada, England, Scotland and Australia: a repeated cross-sectional analysis (2012-2017)

    Greiver, M., Havard, A., Kuster Filipe Bowles, J., Kalia, S., Chen, T., Aliarzadeh, B., Moineddin, R., Sherlock, J., Hinton, W., Sullivan, F., O'Neill, B., Pow, C., Bhatt, A., Rahman, F., Meza-Torres, B., Litchfield, M. & de Lusignan, S., Mar 2021, In: British Journal of General Practice. 71, 704, p. e209-e218

    Research output: Contribution to journalArticlepeer-review

  4. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging

    Sullivan, F. M., Mair, F. S., Anderson, W., Armory, P., Briggs, A., Chew, C., Dorward, A., Haughney, J., Hogarth, F., Kendrick, D., Littleford, R., Mcconnachie, A., McCowan, C., Mcmeekin, N., Patel, M., Rauchhaus, P., Ritchie, L., Robertson, C., Robertson, J., Robles-Zurita, J. & 8 others, Sarvesvaran, J., Sewell, H., Sproule, M., Taylor, T., Tello, A., Treweek, S., Vedhara, K. & Schembri, S., 1 Jan 2021, In: European Respiratory Journal. 57, 1, 11 p., 2000670.

    Research output: Contribution to journalArticlepeer-review

Related by journal

  1. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

    Vasileiou, E., Simpson, C. R., Shi, T., Kerr, S., Agrawal, U., Akbari, A., Bedston, S., Beggs, J., Bradley, D., Chuter, A., de Lusignan, S., Docherty, A. B., Ford, D., Hobbs, FD. R., Joy, M., Katikireddi, S. V., Marple, J., McCowan, C., McGagh, D., McMenamin, J. & 12 others, Moore, E., Murray, J. LK., Pan, J., Ritchie, L., Shah, S. A., Stock, S., Torabi, F., Tsang, R. SM., Wood, R., Woolhouse, M., Robertson, C. & Sheikh, A., 23 Apr 2021, In: The Lancet. 397, 10285, p. 1646-1657

    Research output: Contribution to journalArticlepeer-review

  2. School reopening without robust COVID-19 mitigation risks accelerating the pandemic

    Gurdasani, D., Alwan, N. A., Greenhalgh, T., Hyde, Z., Johnson, L., McKee, M., Michie, S., Prather, K. A., Rasmussen, S. D., Reicher, S., Roderick, P. & Ziauddeen, H., 27 Mar 2021, In: The Lancet. 397, 10280, p. 1177-1178 2 p.

    Research output: Contribution to journalLetter

  3. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3

    Global Burden of Disease Health Financing Collaborator Network & Cevik, M., 23 Apr 2020, In: Lancet. Online First, 32 p.

    Research output: Contribution to journalArticlepeer-review

  4. The COVID-19 vaccines rush: participatory community engagement matters more than ever

    Burgess, R. A., Osborne, R. H., Yongabi, K. A., Greenhalgh, T., Gurdasani, D., Kang, G., Falade, A. G., Odone, A., Busse, R., Martin-Moreno, J. M., Reicher, S. & McKee, M., 10 Dec 2020, In: The Lancet. In Press

    Research output: Contribution to journalComment/debatepeer-review

  5. The UK needs a sustainable strategy for COVID-19

    Gurdasani, D., Bear, L., Bogaert, D., Burgess, R. A., Busse, R., Cacciola, R., Charpak, Y., Colbourn, T., Drury, J., Friston, K., Gallo, V., Goldman, L. R., Greenhalgh, T., Hyde, Z., Kuppalli, K., Majumder, M. S., Martin-Moreno, J. M., McKee, M., Michie, S., Mossialos, E. & 16 others, Nouri, A., Pagel, C., Pimenta, D., Popescu, S., Priesemann, V., Rasmussen, A. L., Reicher, S., Ricciardi, W., Rice, K., Silver, J., Smith, T. C., Wenham, C., West, R., Yamey, G., Yates, C. & Ziauddeen, H., 9 Nov 2020, In: The Lancet. In Press, 2 p.

    Research output: Contribution to journalComment/debate

ID: 258532510

Top